Materias dentro de su búsqueda.
Materias dentro de su búsqueda.
- Society & social sciences 159
- Educación pedagogía 93
- Law 74
- Libros alemanes 67
- Religion 65
- Historia 62
- Humanities 44
- Historia / General 43
- History 43
- Environment 42
- Law and legislation 42
- History / World 41
- Religion / Judaism 34
- Ciencias Políticas / General 33
- Germany 31
- Gewerblicher Rechtsschutz 30
- Colecciones 25
- Philosophy 25
- Chemical tests and reagents 22
- Economics, finance, business & management 22
- Urheberrecht / Gewerblicher Rechtsschutz und Medienrecht 22
- thesis 22
- Literatura griega clásica 20
- Markenrecht 20
- Thèses 20
- Law / Administrative Law & Regulatory Practice 19
- Biografías 17
- Law / Constitutional 17
- Negocios y Economía / Gerencia 17
- Psicología / General 17
-
1101Wahrheit und Recht Störung und Schutz regulatorischer, asylrechtlicher und medialer WahrheitsfindungPublicado 2023Libro electrónico
-
1102
-
1103
-
1104Publicado 2023Libro electrónico
-
1105
-
1106
-
1107
-
1108
-
1109Publicado 2023Libro electrónico
-
1110Publicado 2021Libro electrónico
-
1111
-
1112
-
1113por Organisation for Economic Co-operation and Development.“…A limit test may be performed if no effects would be expected at a dose of 1000 mg/kg bw/d. The results of this study include measurements (weighing) and clinical daily observations, each day preferably at the same time. …”
Publicado 2018
Libro electrónico -
1114por Canadian Agency for Drugs and Technologies in Health“…Emtricitabine/tenofovir alafenamide fumarate (FTC/TAF) (200 mg/10 mg and 200 mg/25 mg) is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors (NRTIs) indicated for use in combination with other antiretroviral therapies (ARTs) for the treatment of HIV type 1 infection in adults and pediatric patients 12 years of age and older (and weighing ≥ 35 kg). It is available as 200 mg/10 mg and 200 mg/25 mg film-coated tablets; the recommended dose is one 200 mg/10 mg tablet daily when used in combination with a ritonavir- or cobicistat (COBI)-boosted protease inhibitor. …”
Publicado 2016
Libro electrónico -
1115
-
1116Publicado 2021Libro electrónico
-
1117
-
1118Publicado 2022Libro electrónico
-
1119
-
1120Publicado 2023Libro electrónico